论文部分内容阅读
前列腺癌(PCa)是一种发病率高、危害性大、死亡率高的疾病。前腺特异性抗原(PSA)与1979年首次定性并分离纯化,它很快成为公认诊断PCa的较好肿瘤标志物。但PSA不具有PCa的特异性,前列腺炎、前列腺增生等前列腺疾病时血中PSA水平均可升高,并且PCa和BPH患者的PSA检测值有一个交叉重叠灰色区域4.0~10.0 ng/ml。所以单纯检测PSA易导致临床诊断PCa产生一定比例的假阳性。目前临床上测
Prostate cancer (PCa) is a disease with high incidence, great harm and high mortality. Prostate-specific antigen (PSA), which was first characterized and isolated in 1979, is rapidly becoming a well-recognized tumor marker for the well-recognized diagnosis of PCa. However, PSA does not have the specificity of PCa. Prostatitis, BPH and other prostate diseases may have elevated serum PSA levels, and PSA levels in PCa and BPH patients range from 4.0 to 10.0 ng / ml with overlapping overlapping gray areas. Therefore, simple detection of PSA easily lead to clinical diagnosis of PCa produce a certain percentage of false positives. The current clinical test